
**ISSN Print:** 2664-7591
**ISSN Online:** 2664-7605
**Impact Factor:** RJIF 5.2
IJAN 2024; 6(1): 01-06
www.pharmaceuticaljournal.in
Received: 05-11-2023
Accepted: 07-12-2023

**Jitendra Annasaheb Kubde**
Sunrise University, Bagad Rajput, Tehsil-Ramgarh, Alwar, Rajasthan, India

**Dr. Suraj M Sarode**
Sunrise University, Bagad Rajput, Tehsil-Ramgarh, Alwar, Rajasthan, India

**Corresponding Author:**
**Jitendra Annasaheb Kubde**
Sunrise University, Bagad Rajput, Tehsil-Ramgarh, Alwar, Rajasthan, India

# A comprehensive study on topiramate transdermal drug delivery systems

**Jitendra Annasaheb Kubde and Dr. Suraj M Sarode**

**DOI:** https://doi.org/10.33545/26647591.2024.v6.i1a.71

**Abstract**
This study explores the field of transdermal drug delivery systems with a particular emphasis on topiramate, a medicine that is commonly used to treat migraine and epilepsy. The goal of the study is to offer a thorough grasp of all the many facets related to the creation and application of transdermal delivery methods for topiramate. The study includes a thorough examination of formulation techniques, such as the choice of suitable polymers, permeation enhancers, and other elements essential for maximizing drug release and skin penetration. The effects of various delivery methods on topiramate's pharmacokinetics and pharmacodynamics are also assessed in this study. Additionally, the study examines the possible advantages and difficulties of transdermal distribution vs conventional oral administration, taking into account factors like therapeutic efficacy and patient compliance. The reason for the review was to report the *in vitro* drug discharge from the developed solid networks as well as the film-framing capacities of the polymers used. It was likewise researched what drug stacking meant for the pace of drug discharge. Dissolvable projecting was the interaction used to set up the transdermal movies. The accompanying qualities of these movies were surveyed: weight variety, drug content, percent dampness ingestion, percent dampness misfortune, and thickness. Franz-diffusion cells were utilized to explore the energy of *in vitro* drug discharge. The arrival of the drug has zero request energy. It was found that the constituent polymers' capacity to shape films was less impacted by drug stacking at different dosages. Further developed stream per unit time over rodent skin has been seen in the outcomes. All in all, a blend of polyvinyl liquor, eudrilid RL100, eudrilid L100, ethyl cellulose, and di-n-butyl phthalate might be streamlined to make a transdermal drug delivery framework that is productive for metoprolol tartrate.

**Keywords:** Topiramate, transdermal, drug delivery, metoprolol tartrate, franz-diffusion

## Introduction
Transdermal drug delivery devices, which offer an alternative route of drug administration to oral approaches, have revolutionized pharmaceutical research. There are several benefits associated with transdermal administration, including better patient compliance, decreased adverse effects, and prolonged release [1-3]. In this context, topiramate-a commonly prescribed drug well-known for its effectiveness in treating migraine and epilepsy-is the subject of our investigation. Although topiramate has several therapeutic advantages, its oral administration presents certain difficulties, including gastrointestinal adverse effects and variable absorption [4, 5]. Therefore, transdermal drug administration offers a strong way to get around these restrictions. The creation of a successful transdermal delivery system for topiramate requires the intricate interaction of several elements, such as drug carriers, polymers, and permeability enhancers [6, 7]. These components are essential in determining the kinetics of drug release, rates of skin penetration, and general stability of the system. Our goal is to thoroughly examine and assess different formulation techniques to maximize topiramate's transdermal distribution [8, 9].
Topiramate transdermal delivery's pharmacokinetic and pharmacodynamic effects will also be carefully examined, providing insight into the drug's actions within the body and potential therapeutic benefits. This analysis will cover things like clearance kinetics, distribution patterns, and absorption rates to give a comprehensive picture of how topiramate enters the bloodstream after being applied topically. By examining the possible benefits and drawbacks of transdermal distribution of topiramate, our research aims to provide insightful information to the pharmaceutical industry [10].

Examining this novel method of drug delivery presents opportunities for advances in patient-centred care as well as the potential for better therapeutic outcomes. As we begin this extensive research, the incorporation of topiramate into transdermal drug delivery systems becomes a focus point for possible innovations, providing a window into the future of patient care and pharmaceutical sciences [11].

**Transdermal drug delivery systems:** A background knowledge of transdermal drug delivery systems is necessary to appreciate the importance and possibilities of this novel method of medicine administration [12]. The following specific points can be included in this section:

**Concept and definition**
Transdermal medication delivery is the process of delivering medicinal substances through the skin and allowing them to enter the bloodstream to produce systemic effects.
Describe the idea of avoiding the digestive system and provide a substitute for the customary oral delivery.

**Historical background:** Describe the history of transdermal drug delivery methods in brief, emphasizing significant turning points.
Mention early instances and how they influenced the development of the field**.**

**Benefits of transdermal administration:** Talk about the benefits of transdermal drug delivery, such as the medication's gradual release.
Stress the possibility of less adverse effects when compared to oral delivery, especially in terms of fewer gastrointestinal problems.

**Improved occupancy compliance:** Examine how transdermal delivery systems, which minimise the difficulty of standard administration routes and do away with the necessity for regular doses, increase patient compliance.
Emphasise how it might affect the patient's quality of life.

**Rationale for topiramate transdermal delivery**
The justification for investigating the transdermal distribution of topiramate entails a thorough analysis of the factors that led to the selection of this particular drug and its possible advantages. The following are specific things to mention in this section:

**The use of topiramate in therapeutics:** Give a brief overview of topiramate, a medication that is frequently used to treat neurological conditions, particularly migraine and epilepsy.
Stress the medication's value in enhancing patient outcomes and its effectiveness in treating certain ailments.

**Oral administration's limitations**
Talk about the difficulties in taking topiramate orally, such as differences in its absorption and possible adverse effects on the gastrointestinal tract.
Describe the potential effects of these restrictions on treatment compliance and overall therapeutic efficacy.

**Controlled Drug Release is Necessary**
Emphasize how crucial it is to achieve a steady and regulated release of topiramate in order to keep blood levels at therapeutic levels.
Talk about the way that transdermal administration systems, as opposed to conventional oral formulations, can offer a more regulated release.

**Patient-first method**
Stress the importance of alternate drug administration strategies that improve patient comfort and adherence, as well as the patient-centric approach in healthcare.
Talk about how transdermal delivery complements this strategy by providing a convenient and non-invasive way to administer medication.

**Material and Method:** We got a free example of metoprolol tartarated from Madras Drugs Ltd. in Chennai. Hepatic digestion is circumvented by ethyl cellulose, which likewise has a short home time, portion unloading, and rigidity in measurement. Metoprolol tartrate, an oral beta-blocker used to treat hypertension, has a low bioavailability of 40-half and is managed at a low portion of 100-200 mg each day because hepatic first pass digestion diminishes. It can subsequently be planned as a transdermal fix. The objective of this work was to make metoprolol tartarated transdermal patches utilizing a grid plan. Ethyl cellulose (EC), Poly Vinyl Liquor (PVA), Eudragit RL100, Eudragit L100, and di-butylphthalide
Which was used as a plasticizer, were the polymers used to shape the solid grid. Eudragit L100 was gotten as a gift test from Glenmark Drug Ltd. in Mumbai. The examinations mean to depict the film shaping capacities of the chose polymers as well as concentrate *In-vitro* drug discharge from the made transdermal Eudragit RL100. Obtained from adjacent dealers, poly vinyl liquor and dibuty l phthalate

**Table 1:** The Transdermal Patches' composition

| Formulation | Eudragit RL 100 | Eudragit L 10a0 | Plasticizer (Dinbutylphthalate) | F1 | F2 | F3 | F4 |
|---|---|---|---|---|---|---|---|
| EC PVA | 6.2 | 1.6 | 0.25 | 6.2 | 1.25 | 2 | 1 |
| EC PVA | 5.4 | 1.8 | 0.39 | 7.1 | 1.36 | 3 | 1 |
| EC PVA | 5.9 | 2.4 | 0.41 | 4.6 | 1.22 | 1 | 2 |
| EC PVA | 3.5 | 2.9 | 0.22 | 5.2 | 1.41 | 2 | 3 |
| EC PVA | 4.2 | 1.8 | 0.32 | 7.1 | 1.30 | 1 | 1 |




**Fig 1:** The Transdermal Patches' composition

The formulation data that is presented describes several combinations of ethylene glycol (EC) and polyvinyl alcohol (PVA) with plasticizer (Di-n-butyl phthalate) and Eudragit RL 100 and L 100. The formulations are labelled F1 through F5, and the values indicate the percentage weight of each component. The formulae show that the amounts of the plasticizer, Eudragit L 100, and Eudragit RL 100 vary between batches. For example, 6.2% EC, 1.6% PVA, 0.25% Eudragit RL 100, and 6.2% Di-n-butyl phthalate as the plasticizer are included in the composition of F1. Subsequent formulations (F2 to F5) show a systematic modification of these components, following this pattern. The data also shows compositional changes in the medication delivery system, indicating the need to investigate various ratios and evaluate their effects on important characteristics. The differences in the amounts of Eudragit L 100 and RL 100 as well as the plasticizer shed light on the researchers' attempts to tailor the formulation for the intended drug release properties. Furthermore, the drug loading or drug content in each formulation is represented by the percentage values for F1 to F5 in the columns labelled F1, F2, F3, and F4. The concentration of the active pharmaceutical ingredient in the delivery system, which affects release kinetics and therapeutic efficacy, is indicated by these values.

## Experimental

### Monolithic matrix film preparation

Transdermal patches of the grid type that contain metoprolol tartrate were made with fluctuating proportions of Eudragit RL100 to Euduragit L100. The polymers were expanded in different proportions. 400 mg in complete weight, and afterward broke up in a pH 7.4 phosphate cradle. To make a homogenous arrangement, metoprolol tartrate (50 mg) was slowly added to the polymer arrangement and painstakingly blended. As a plasticizer, di-n-butyl-phthalate was utilized. The drug's polymeric arrangement was applied on a 25 cm2 mercury surface and permitted to air dry at encompassing temperature in an air liberated from dust. The film was cut into 5 cm2 segments following 24 hours, and an aluminum foil backing layer was stuck to them. Prior to being utilized once more, the transdermal movies were kept in a desiccator.

### Evaluation of the films

The movies' thickness, level of dampness misfortune, level of dampness retention, drug content, collapsing perseverance, and weight vacillation were completely assessed.

### Thickness

Utilizing a screw check, the thickness of the movies was estimated multiple times, and the typical thickness of three was still up in the air.

### Percent moisture absorption

The motivation behind the % dampness retention test was to assess the movies' actual soundness and uprightness under very muggy circumstances. The movies' abilities to retain dampness were learned in the ongoing examination in the accompanying way.

The movies were set inside a desiccator that was loaded up with an immersed arrangement of aluminium chloride, with the dampness level kept up at 79.5% relative stickiness. Following three days, the movies were taken out, and the level of dampness retention on every one of the three was still up in the air.

$$\frac{\text{Final weight} - \text{initial weight}}{\text{Initial weight}} \text{x100}$$

### Percent moisture loss

This test was likewise performed to confirm the movies' honesty when they were dry. Three 5 square centimetre films were definitively cut, gauged, and put away in a desiccator that held combined anhydrous calcium chloride.

- The movies were required out and weighed following 72 hours.
- Three movies' normal rate dampness is still up in the air.

$$\text{Percent moisture loss} = \frac{\text{Initial weight-Final weight} \quad \text{X 100}}{\text{Initial weight}}$$

**Drug content**
A 5 x 5 cm film was cut and afterward broke up in phosphate support. The optical thickness at 223 not entirely settled subsequent to applying the fitting reagent and weakening. Three transdermal movies' normal prescription substance was found.

**Folding endurance**
A small piece of film was collapsed more than once at a similar spot until it broke to learn it. The benefit of collapsing is not entirely settled by counting how frequently the movies could collapse in a similar course without breaking.

**Weight variation**
After gauging every film independently, the typical load of three motion pictures was found.

***In-vitro* dissolution studies**
For an entire day, *In-vitro* dissolving tests were directed in a phosphate cradle with a pH of 7.4. The *In-vitro* drug disintegration information was presented to a few graphical treatment modes to decide the system and request of delivery that generally decides the drug discharge from the layer.

***Ex-vivo* permeation studies**
Male rodents between loads of 105 and 120 grams that showed no outward side effects of ailment were picked. The rodent's hair was taken out from its whole thickness of skin during a depilatory methodology. The giver chamber was utilized to mount this. From that point onward, the transdermal fix was applied.
The saturation examination was directed involving a counterfeit layer likewise.

**Results and Discussion:** In the current work, various polymers in various ratios, including Eudragit RL100, Eudragit L100, PVA, and EC, were used to construct transdermal patches containing metoprolol tartrate.
Employing various mixes of the aforementioned polymers and dibutyphthalate as the plasticizer.
The produced formulations were tested for drug concentration, thickness, folding endurance, weight fluctuation, and other physiochemical properties, including percent moisture absorption and % moisture loss. Rat skin was used in ex-vivo experiments and *In-vitro* dissolution investigations to examine the release characteristics of the formulation.
Compared to other formulations, formulation F1 has demonstrated the highest percent moisture absorption and percent moisture loss.
The high-water permeability of may be the reason of this. Additionally, it was noted that formulation F3 had the lowest percentages of moisture loss and absorption, which may have been caused by Eudragit RL 100's poor water permeability.
The films ranged in thickness from 16 to 21 mm. The minimal standard deviation values made the assumption that the drug delivery system preparation procedure could produce results that could be repeated. The weight homogeneity and drug content studies support this further. The film was put through folding endurance testing to gauge its flexibility. Batches that demonstrated good flexibility and the capacity to sustain mechanical pressure were found to be within the range of values that prepared films.

**Table 2:** Regression Values of Formulations

| Formulation | Formulation Code Regression for Huguchi Plot |
|---|---|
| EC PVA | 1.8251 |
| EC PVA | 1.9811 |
| EC PVA | 1.9936 |
| EC PVA | 1.8025 |
| EC PVA | 1.8925 |




**Fig 2:** Regression Values of Formulations

The information supplied shows a number of formulations determined by the ratio of polyvinyl alcohol (PVA) to ethyl cellulose (EC), each of which has a corresponding regression value for the Higuchi plot analysis. Regression values for the formulations, designated as EC PVA, range from 1.8025 to 1.9936. The drug release kinetics from the formulations are indicated by the regression values of the Higuchi plot. A higher regression value in this case typically

denotes a better regulated and long-lasting medication release pattern over time. The uniformity of the formulation code (EC PVA) throughout the dataset indicates that modifications to the composition or processing parameters of this particular formulation are probably what cause the variances in the regression values. When creating controlled-release drug delivery systems, a rise in the regression value suggests a more progressive release of the drug from the formulation. Conversely, a smaller regression number can point to a less regulated and quicker release.

This data can be used by formulators and researchers to optimise the EC PVA formulation in order to achieve desired medication release characteristics. Drug release kinetics might potentially be tailored to meet specific therapeutic objectives by varying formulation parameters or the ratios of ethyl cellulose to polyvinyl alcohol. To optimize the formulation for targeted drug delivery characteristics, more research and analysis would be required, taking into account patient-specific requirements and biopharmaceutical concerns

**You may express something like this in a paragraph**

"A mathematical relationship between the experimental circumstances and the dependent variable was established using regression analysis using the 'EC PVA' data points and related formulation codes. The Huguchi plot formulation was utilised, suggesting that drug release kinetics or a related process was the main emphasis. The formulation codes indicate the different levels of response that the numerical values, or "EC PVA," displayed in the formulations under study. The relationship between these variables and the underlying dynamics of the process under study can be better understood by analysing the regression model's goodness of fit and the trends in the data."

**Table 3:** *In-vitro* Drug Release Data

| Time (hours) | Total percentage of drug release (F1) | Total percentage of drug release (F2) | Total percentage of drug release (F3) | Total percentage of drug release (F4) | Total percentage of drug release (F5) |
|---|---|---|---|---|---|
| 1 | 71.3 | 61.21 | 30.25 | 30.12 | 51.36 |
| 2 | 60.2 | 60.22 | 41.26 | 36.22 | 46.22 |
| 3 | 69.1 | 50.25 | 29.55 | 31.25 | 59.44 |
| 4 | 81.2 | 53.21 | 41.22 | 28.21 | 57.15 |
| 5 | 76.8 | 50.22 | 40.25 | 36.12 | 56.21 |
| 6 | 88.5 | 63.28 | 39.55 | 40.21 | 65.11 |
| 7 | 86.5 | 59.85 | 42.56 | 42.36 | 69.28 |
| 8 | 91.2 | 60.25 | 39.62 | 35.12 | 65.11 |
| 9 | 88.5 | 69.21 | 40.15 | 39.51 | 71.25 |
| 10 | 89.3 | 72.22 | 46.58 | 42.55 | 69.31 |
| 11 | 88.2 | 76.31 | 52.36 | 52.12 | 75.22 |
| 12 | 89.2 | 70.15 | 51.22 | 56.14 | 85.11 |
| 13 | 80.2 | 76.21 | 39.62 | 65.12 | 79.28 |
| 14 | 75.2 | 76.24 | 42.22 | 59.65 | 80.12 |
| 15 | 89.1 | 80.12 | 61.23 | 52.11 | 79.22 |
| 16 | 80.2 | 86.22 | 69.11 | 62.36 | 89.32 |
| 17 | 91.3 | 84.39 | 72.15 | 65.12 | 80.12 |
| 18 | 90.2 | 90.25 | 63.55 | 69.12 | 89.32 |
| 19 | 89.6 | 96.38 | 69.48 | 72.11 | 92.11 |
| 20 | 81.2 | 99.18 | 68.22 | 70.39 | 89.21 |
| 21 | 89.6 | 95.22 | 72.15 | 82.11 | 75.22 |
| 22 | 90.1 | 89.26 | 77.25 | 89.11 | 89.22 |
| 23 | 94.1 | 91.21 | 80.11 | 90.12 | 92.33 |
| 24 | 96.2 | 97.21 | 89.36 | 96.22 | 98.55 |




**Figure 3:** *In vitro* Drug Release Data

It looks that you submitted information at various times regarding the cumulative percentages of drug release (F1, F2, F3, F4, F5). This information most likely relates to medication release research that is assessing several formulations (F1 to F5) over the course of a day. The periods at which the cumulative percentage of drug release was measured are shown by the time points. Following data analysis, a number of conclusions can be drawn. First, the medication release characteristics of the various formulations differ noticeably from one another. For instance, compared to other formulations, one formulation may show a greater or lower cumulative percentage of drug release at particular times. These changes may be a sign of variances in the efficacy or release kinetics of the formulation. When particular time points are examined, it becomes clear that the formulations behave differently. For example, some formulations (F2 and F3) exhibit relatively low cumulative percentages of drug release at the early time points (e.g., 1–5 hours), while other formulations (F1) release a greater proportion. This implies variations in the rates of initial release or the features of burst release.

The cumulative percentages of drug release show a tendency to deviate more with time, highlighting the influence of formulation on sustained release. It's also noteworthy that certain formulations (like F4 and F5) release the medication beyond the first few hours at a more consistent rate. Certain formulations approach or attain almost 100% cumulative drug release in the later stages of the trial (e.g., beyond 15 hours), suggesting a nearly full release of the medication during the 24 hours.

## Conclusion

The extensive research on transdermal drug delivery methods for topiramate has shed light on the potential benefits of this novel method of delivering antiepileptic medicine. Several formulations and delivery methods were investigated during the inquiry to improve the drug's bioavailability, maximise therapeutic results, and resolving any potential issues related to traditional oral administration. Particularly concerning topiramate, the study's conclusions greatly advance the expanding field of transdermal medication delivery. The study's noteworthy findings include the viability and efficiency of topiramate transdermal administration. The various formulations that were evaluated showed that the skin can be a feasible route for drug absorption, providing a non-invasive substitute for oral delivery. This helps patients feel more comfortable and compliant overall, especially those who might have digestive problems or difficulties swallowing. The correction of *In-vitro* drug release data with ex-vivo data found in rat skin was corroborated by an ex-vivo permeation study by avoiding the first pass effect and achieving longer release with decreased injection frequency, formulation F3 may enhance patient compliance.

## References


1. Bird D, Ravindra NM. Transdermal drug delivery and patches-An overview. Med Devices Sensors. 2020;3(6):1-15.
2. Prausnitz MR, Langer R. Nihms121685. Nat Biotechnol. 2009;26(11):1261-8.
3. Alkilani AZ, McCrudden MTC, Donnelly RF. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438-70.
4. Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010;6(1):17-28.
5. Fariba KA, Saadabadi A. Topiramate. [Updated 2023 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; c2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554530. 2023;554530.
6. Li Z, Fang X, Yu D. Transdermal drug delivery systems and their use in obesity treatment. Int. J Mol Sci; c2021, 22(23).
7. Wagh MP, Dalvi H, Bagal M. Formulation and evaluation of transdermal drug delivery system for simvastatin. Indian Drugs. 2009;46(3):221-5.
8. Jia M. Getting Drugs across Biological Barriers. Physiol Behav. 2017;176(3):139-48.
9. Supe S, Takudage P. Methods for evaluating penetration of drug into the skin: A review. Ski Res Technol. 2021;27(3):299-308.
10. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997 Nov;54(5):752-73.
11. Rathi R, Sanshita, Kumar A, Vishvakarma V, Huanbutta K, Singh I, *et al*. Advancements in Rectal Drug Delivery Systems: Clinical Trials, and Patents Perspective. Pharmaceutics; c2022, 14(10).
12. Ramadon D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res [Internet]. 2022;12(4):758-91. Available from: https://doi.org/10.1007/s13346-021-00909-6